Clinical Trials Snapshot

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Phase I/II trial evaluating how well genetically modified therapeutic autologous lymphocytes followed by aldesleukin work in treating patients with stage III melanoma or melanoma that has spread to other places in the body.

Melanoma scorecard

Phase I/II trial evaluating how well genetically modified therapeutic autologous lymphocytes followed by aldesleukin work in treating patients with stage III melanoma or melanoma that has spread to other places in the body.

Melanoma scorecard